AUPH (Aurinia Pharmaceuticals) PEG Ratio: N/A (As of Jul. 04, 2026)


AUPH Aurinia Pharmaceuticals Inc AUPH
81 GF Score
Price $15.61
GF Value $14.00
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Aurinia Pharmaceuticals's PE Ratio without NRI is 7.19. Aurinia Pharmaceuticals's 5-Year EBITDA growth rate is 0.00%. Therefore, Aurinia Pharmaceuticals's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Aurinia Pharmaceuticals's PEG Ratio or its related term are showing as below:



AUPH's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.02
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Aurinia Pharmaceuticals  (NAS:AUPH) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Aurinia Pharmaceuticals PEG Ratio Related Terms


Aurinia Pharmaceuticals PEG Ratio Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals PEG Ratio Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aurinia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AUPH vs KOD, ABCL, AGIO: PEG Ratio Comparison

For the Biotechnology subindustry, Aurinia Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's PEG Ratio falls into.


AUPH
81GF Score
Aurinia Pharmaceuticals Inc AUPH
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurinia Pharmaceuticals PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Aurinia Pharmaceuticals's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=7.1902349147858/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of $15.61 is trading 11.5% above its estimated GF Value™ of $14.00. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for AUPH:

  • PEG Ratio: N/A
  • GF Value™: $14.00 vs. price of $15.61 (11.5% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aurinia Pharmaceuticals Business Description

Other Exchanges IKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
81GF Score

Get the complete analysis for AUPH

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.61
Price
$14.00
GF Value